As filed with the Securities and Exchange Commission on June 18, 2008
Registration No. 333-
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM S-8
REGISTRATION STATEMENT UNDER
THE SECURITIES ACT OF 1933
AVANT IMMUNOTHERAPEUTICS, INC.
(Exact Name of Registrant as Specified in its Charter)
Delaware |
|
13-3191702 |
(State or Other Jurisdiction |
|
(I.R.S. Employer Identification No.) |
of Incorporation or Organization) |
|
|
119 FOURTH AVENUE
NEEDHAM, MASSACHUSETTS 02494
(781) 433-0771
(Address of Principal Executive Offices)
AVANT IMMUNOTHERAPEUTICS, INC. 2008 STOCK OPTION AND INCENTIVE PLAN*
CELLDEX THERAPEUTICS, INC. 2005 EQUITY INCENTIVE PLAN*
(Full Title of the Plans)
* See explanatory note on following page
Anthony S. Marucci
Chief Executive Officer
AVANT Immunotherapeutics, Inc.
119 Fourth Avenue
Needham, Massachusetts 02494
(781) 433-0771
(Name and Address of Agent For Service)
With copies to:
Ettore A. Santucci, P.C.
John T. Haggerty, P.C.
Goodwin Procter LLP
Exchange Place
Boston, Massachusetts 02109-2881
(617) 570-1000
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See definitions of large accelerated filer, accelerated filer, and smaller reporting company in Rule 12b-2 of the Exchange Act. (Check one):
|
Large accelerated filer o |
|
Accelerated filer x |
|
|
|
|
|
Non-accelerated filer o |
|
Smaller Reporting Company o |
|
(Do not check if a smaller reporting company) |
|
|
CALCULATION OF REGISTRATION FEE
Title of Securities |
|
Amount |
|
Proposed Maximum |
|
Proposed Maximum |
|
Amount of |
|
|||
Common Stock, $.001 par value |
|
1,500,000 shares |
(2) |
$ |
16.36 |
(5) |
$ |
24,532,500 |
(5) |
$ |
964.13 |
|
Common Stock, $.001 par value |
|
1,446,914 shares |
(3)(4) |
$ |
8.16 |
(6) |
$ |
11,806,818.24 |
(6) |
$ |
464.01 |
|
(1) This Registration Statement also relates to rights to purchase shares of Series C-1 Junior Participating Cumulative Preferred Stock of the Company which are attached to all shares of Common Stock issued, pursuant to the terms of the Companys Shareholder Rights Agreement dated November 5, 2004 (as amended). Until the occurrence of certain prescribed events, the Rights are not exercisable, are evidenced by the certificates for the Common Stock and will be transferred with and only with such stock. Because no separate consideration is paid for the rights, the registration fee therefor is included in the fee for the Common Stock.
(2) This Registration Statement also relates to such indeterminate number of additional shares of Common Stock as may be required pursuant to the AVANT Immunotherapeutics, Inc. 2008 Stock Option and Incentive Plan (the AVANT Plan) in the event of a stock dividend, reverse stock split, split-up, recapitalization, forfeiture of stock under the plan or other similar event.
(3) This Registration Statement also relates to such indeterminate number of additional shares of Common Stock as may be required pursuant to the Celldex Therapeutics, Inc. 2005 Equity Incentive Plan (the Celldex Plan) in the event of a stock dividend, reverse stock split, split-up, recapitalization, forfeiture of stock under the plan or other similar event.
(4) This Registration Statement relates to 1,446,914 shares of Common Stock that may be issued upon the exercise of options issued under the Celldex Plan, which options were assumed by AVANT Immunotherapeutics, Inc. in connection with an Agreement and Plan of Merger, dated October 19, 2007, by and among the Company, Callisto Merger Corporation and Celldex Therapeutics, Inc.
(5) Estimated solely for purposes of determining the registration fee pursuant to Rule 457(c) and (h) under the Securities Act of 1933, as amended, based on the average of the high and low sales prices on the Nasdaq Global Market on June 13, 2008.
(6) Estimated solely for purposes of determining the registration fee pursuant to Rule 457(h) under the Securities Act of 1933, as amended, the price at which the options may be exercised, based on the average of the high and low sales prices on the Nasdaq Global Market on March 7, 2008, the grant date of the options.
PART I
INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS
Item 1. Plan Information.*
Item 2. Registrant Information and Employee Plan Annual Information.*
* Information required by Part I to be contained in the Section 10(a) Prospectus is omitted from this Registration Statement in accordance with Rule 428 under the Securities Act of 1933, as amended (the Securities Act), and the Introductory Note to Part I of Form S-8.
EXPLANATORY NOTE:
This Registration Statement on Form S-8 is being filed by the registrant to register (i) 1,500,000 shares of AVANT Immunotherapeutics, Inc. (the Company) Common Stock par value $.001 per share (Common Stock) that may be issued upon the exercise of options issued under the Companys 2008 Stock Option and Incentive Plan (the AVANT Plan), and (ii) 1,446,914 shares of Common Stock that may be issued upon the exercise of options issued under Celldex Therapeutics, Incs 2005 Equity Incentive Plan (the Celldex Plan), which options were assumed by the Company in connection with an Agreement and Plan of Merger, dated October 19, 2007, by and among the Company, Callisto Merger Corporation and Celldex Therapeutics, Inc.
2
Part II
INFORMATION REQUIRED IN THE REGISTRATION STATEMENT
Item 3. Incorporation of Documents by Reference.
The following documents, which have been filed with or furnished to the Securities and Exchange Commission (the Commission) by the registrant are incorporated herein by reference and made a part hereof:
· The registrants Annual Report on Form 10-K for the year ended December 31, 2007.
· The registrants Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2008.
· The registrants Registration Statement on Form S-4 (Reg. No. 333-148291), filed December 21, 2007 and all amendments updating such registration statement.
· The registrants Current Reports on Form 8-K filed with the Commission on January 9, 2008, January 16, 2008, February 12, 2008, February 27, 2008, March 11, 2008 (as amended May 23, 2008), April 17, 2008, May 14, 2008, May 30, 2008 and June 9, 2008.
· The description of the Registrants Common Stock contained in its Registration Statement on Form 8-A, filed with the Commission on September 22, 1986 under Section 12 of the Securities Exchange Act of 1934, as amended (the Exchange Act), and any amendments or reports filed for the purpose of updating such description.
· The description of the rights to purchase shares of the Registrants Series C-1 Junior Participating Cumulative Preferred Stock contained in the Registrants Registration Statement on Form 8-A, filed on November 14, 1994, and all amendments and reports updating such description.
All documents filed by the registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act subsequent to the effective date of this Registration Statement, prior to the filing of a post-effective amendment to this Registration Statement indicating that all securities offered hereby have been sold or deregistering all securities then remaining unsold, shall be deemed to be incorporated by reference herein and to be a part hereof from the date of filing of such documents. Any statement contained herein or in any document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed to constitute a part of this Registration Statement, except as so modified or superseded.
Item 4. Description of Securities.
Not applicable.
Item 5. Interests of Named Experts and Counsel.
None.
Item 6. Indemnification of Directors and Officers.
The Company is a Delaware corporation. In accordance with the Delaware General Corporation Law (the DGCL), Article Six of the registrants Third Restated Certificate of Incorporation, as amended, provides that no director of the registrant shall be personally liable to the registrant or its stockholders for breach of fiduciary duty as a director, except for liability (i) for any breach of the directors duty of loyalty to the Company or its stockholders, (ii) for acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law, (iii) under Section 174 of the DGCL, or (iv) for any transaction from which the director derived an improper personal benefit.
The DGCL permits, but does not require, a corporation to indemnify its directors, officers, employees or agents and expressly provides that the indemnification provided for under the DGCL shall not be deemed exclusive of any indemnification right under any bylaw, agreement, vote of stockholders or disinterested directors, or otherwise. The DGCL permits indemnification against expenses and certain other liabilities arising out of legal
3
actions brought or threatened against such persons for their conduct on behalf of the corporation, provided that each such person acted in good faith and in a manner that he or she reasonably believed was in or not opposed to the corporations best interests and in the case of a criminal proceeding, had no reasonable cause to believe his or her conduct was unlawful. The DGCL does not allow indemnification of directors in the case of an action by or in the right of the corporation (including stockholder derivative suits) unless the directors successfully defend the action or indemnification is ordered by the court. The Amended and Restated Bylaws of the Company (the Bylaws) provide for indemnification to the directors, officers, employees and agents of the Company consistent with that authorized by the DGCL. Insofar as indemnification for liabilities arising under the Securities Act of 1933, as amended, may be permitted to directors and officers of the Company pursuant to the foregoing provision or otherwise, the Company has been advised that, in the opinion of the Securities and Exchange Commission, such indemnification is against public policy as expressed in the Securities Exchange Act of 1934, as amended, and is therefore, unenforceable.
The Company currently carries a directors and officers liability insurance policy which provides for payment of expenses of the Companys directors and officers in connection with threatened, pending or completed actions, suits or proceedings against them in their capacities as directors and officers, in accordance with the Bylaws and the DGCL.
Item 7. Exemption from Registration Claimed.
Not applicable.
Item 8. Exhibits.
No. |
|
Description |
|
Location |
2.1 |
|
Agreement and Plan of Merger, dated as of October 19, 2007, by and among AVANT, Celldex Merger Corporation, and Celldex Therapeutics, Inc. |
|
Incorporated by reference to Exhibit 2.1 of AVANTs Registration Statement on Form S-4 (Reg. N. 333-148291), filed December 21, 2007 |
|
|
|
|
|
3.1 |
|
Third Restated Certificate of Incorporation of AVANT |
|
Incorporated by reference to Exhibit 3.1 of AVANTs Registration Statement on Form S-4 (Reg. No. 333-59215), filed July 16, 1998 |
|
|
|
|
|
3.2 |
|
Certificate of Amendment of Third Restated Certificate of Incorporation of AVANT |
|
Incorporated by reference to Exhibit 3.1 of AVANTs Registration Statement on Form S-4 (Reg. No. 333-59215), filed July 16, 1998 |
|
|
|
|
|
3.3 |
|
Second Certificate of Amendment of Third Restated Certificate of Incorporation of AVANT |
|
Incorporated by reference to Exhibit 3.2 of AVANTs Registration Statement on Form S-4 (Reg. No. 333-59215), filed July 16, 1998 |
|
|
|
|
|
3.4 |
|
Third Certificate of Amendment of Third Restated Certificate of Incorporation of AVANT |
|
Incorporated by reference to Exhibit 3.1 of AVANTs Quarterly Report on Form 10-Q, filed May 10, 2002 |
|
|
|
|
|
3.5 |
|
Amended and Restated By-Laws of AVANT as of March 14, 2007 |
|
Incorporated by reference to Exhibit 3.5 of AVANTs Annual Report on Form 10-K, filed March 18, 2008 |
|
|
|
|
|
3.6 |
|
Certificate of Elimination of Series C-1 Junior Participating Cumulative Preferred Stock |
|
Incorporated by reference to Exhibit 3.6 of AVANTs Annual Report on Form 10-K, filed March 16, 2005 |
|
|
|
|
|
3.7 |
|
Certificate of Designations, Preferences and Rights of a Series of Preferred Stock of AVANT Immunotherapeutics, Inc. classifying and designating the Series C-1 Junior Participating Cumulative Preferred Stock |
|
Incorporated by reference to Exhibit 3.1 of AVANTs Registration Statement on Form 8-A filed November 8, 2004 |
|
|
|
|
|
3.8 |
|
Fourth Certificate of Amendment of Third Restated Certificate of Incorporation of AVANT |
|
Incorporated by reference to Exhibit 3.1 of AVANTs Current Report on Form 8-K filed on March 11, 2008 |
|
|
|
|
|
3.9 |
|
Fifth Certificate of Amendment of Third Restated Certificate of Incorporation of AVANT |
|
Incorporated by reference to Exhibit 3.2 of AVANTs Current Report on Form 8-K filed on March 11, 2008 |
|
|
|
|
|
4.1 |
|
Shareholder Rights Agreement dated November 5, 2004 between AVANT and EquiServe Trust Company, N.A. as Rights Agent |
|
Incorporated by reference to Exhibit 4.1 of AVANTs Registration Statement on Form 8-A filed November 8, 2004 |
|
|
|
|
|
4.2 |
|
Amendment No. 1 to Shareholder Rights Agreement dated October 19, 2007 between AVANT and Computershare Trust Company, N.A. (formerly EquiServe Trust Company, N.A.) as Rights Agent |
|
Incorporated by reference to Exhibit 10.1 of AVANTs Registration Statement on Form 8-A/A filed October 22, 2007 |
|
|
|
|
|
4.3 |
|
Amendment No. 2 to Shareholder Rights Agreement dated |
|
Incorporated by reference to Exhibit 10.1 of AVANTs |
4
|
|
November 5, 2004, between the Company and Computershare Trust Company, N.A. (formerly EquiServe Trust Company, N.A.), as Rights Agent. |
|
Registration Statement on Form 8-A12G/A filed on March 7, 2008. |
|
|
|
|
|
5.1 |
|
Opinion of Goodwin Procter LLP as to the legality of the securities being registered |
|
Filed herewith |
|
|
|
|
|
10.1 |
|
Celldex Therapeutics, Inc. 2005 Equity Incentive Plan |
|
Filed herewith |
|
|
|
|
|
10.2 |
|
AVANT Immunotherapeutics, Inc. 2008 Stock Option and Incentive Plan |
|
Incorporated by reference to Exhibit 10.3 to a Current Report on Form 8-K filed by AVANT on October 22, 2007 |
|
|
|
|
|
23.1 |
|
Consent of PricewaterhouseCoopers LLP, Independent Registered Public Accounting Firm |
|
Filed herewith |
|
|
|
|
|
23.2 |
|
Consent of Ernst & Young LLP, Independent Registered Public Accounting Firm of Celldex Therapeutics, Inc. |
|
Filed herewith |
|
|
|
|
|
23.3 |
|
Consent of Goodwin Procter LLP |
|
Included in Exhibit 5.1 hereto |
|
|
|
|
|
24.1 |
|
Powers of Attorney |
|
Included on signature pages to this Registration Statement |
Indicates a management contract or compensation plan, contract or arrangement.
Item 9. Undertakings.
(a) The undersigned registrant hereby undertakes:
(1) To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:
(i) To include any prospectus required by section 10(a)(3) of the Securities Act of 1933;
(ii) To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20% change in the maximum aggregate offering price set forth in the Calculation of Registration Fee table in the effective registration statement;
(iii) To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement;
Provided, however, that Paragraphs (a)(1)(i) and (a)(1)(ii) of this section shall not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the registrant pursuant to section 13 or section 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m or 78o(d)) that are incorporated by reference in the registration statement.
(2) That, for the purpose of determining any liability under the Securities Act of 1933, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.
(3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.
(4) That, for the purpose of determining liability under the Securities Act of 1933 to any purchaser: each prospectus filed pursuant to Rule 424(b) as part of a registration statement relating to an offering, other than registration statements relying on Rule 430B or other than prospectuses filed in reliance on Rule 430A, shall be deemed to be part of and included in the registration statement as of the date it is first used after effectiveness; provided, however,
5
that no statement made in a registration statement or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such first use, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately prior to such date of first use.
(5) That, for the purpose of determining liability of the registrant under the Securities Act of 1933 to any purchaser in the initial distribution of the securities:
The undersigned registrant undertakes that in a primary offering of securities of the undersigned registrant pursuant to this registration statement, regardless of the underwriting method used to sell the securities to the purchaser, if the securities are offered or sold to such purchaser by means of any of the following communications, the undersigned registrant will be a seller to the purchaser and will be considered to offer or sell such securities to such purchaser:
(i) Any preliminary prospectus or prospectus of the undersigned registrant relating to the offering required to be filed pursuant to Rule 424;
(ii) Any free writing prospectus relating to the offering prepared by or on behalf of the undersigned registrant or used or referred to by the undersigned registrant;
(iii) The portion of any other free writing prospectus relating to the offering containing material information about the undersigned registrant or its securities provided by or on behalf of the undersigned registrant; and
(iv) Any other communication that is an offer in the offering made by the undersigned registrant to the purchaser.
(b) The undersigned registrant hereby undertakes that, for purposes of determining any liability under the Securities Act of 1933, each filing of the registrants annual report pursuant to section 13(a) or section 15(d) of the Securities Exchange Act of 1934 (and, where applicable, each filing of an employee benefit plans annual report pursuant to section 15(d) of the Securities Exchange Act of 1934) that is incorporated by reference in the registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.
(c) Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Act and will be governed by the final adjudication of such issue.
6
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Needham, Commonwealth of Massachusetts, on this 17th day of June, 2008.
|
AVANT Immunotherapeutics, Inc. |
|
|
|
|
|
|
|
|
|
|
|
By: |
/s/ Avery W. Catlin |
|
|
|
Avery W. Catlin |
|
|
|
Senior Vice President and |
|
|
|
Chief Financial Officer |
|
KNOW ALL BY THESE PRESENTS that each individual whose signature appears below constitutes and appoints Anthony S. Marucci and Avery W. Catlin, and each of them singly, as such persons true and lawful attorney-in-fact and agent with full power of substitution and resubstitution, for such person in such persons name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement, and to file the same, with all exhibits thereto, and all documents in connection therewith, with the Securities and Exchange Commission, granting unto each said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as such person might or could do in person, hereby ratifying and confirming all that any said attorney-in-fact and agent, or any substitute or substitutes of any of them, may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the date indicated.
Signatures |
|
Title |
|
Date |
|
|
|
|
|
/s/ Charles R. Schaller |
|
Chairman |
|
June 17, 2008 |
Charles R. Schaller |
|
|
|
|
|
|
|
|
|
/s/ Anthony S. Marucci |
|
Chief Executive Officer |
|
June 17, 2008 |
Anthony S. Marucci |
|
(Principal Executive Officer) |
|
|
|
|
|
|
|
/s/ Avery W. Catlin |
|
Senior Vice President and Chief Financial Officer |
|
June 17, 2008 |
Avery W. Catlin |
|
(Principal Financial Officer and |
|
|
|
|
Principal Accounting Officer) |
|
|
|
|
|
|
|
/s/ George O. Elston |
|
Director |
|
June 17, 2008 |
George O. Elston |
|
|
|
|
|
|
|
|
|
/s/ Herbert J. Conrad |
|
Director |
|
June 17, 2008 |
Herbert J. Conrad |
|
|
|
|
|
|
|
|
|
/s/ Rajesh B. Parekh |
|
Director |
|
June 17, 2008 |
Dr. Rajesh B. Parekh |
|
|
|
|
|
|
|
|
|
/s/ Larry Ellberger |
|
Director |
|
June 17, 2008 |
Larry Ellberger |
|
|
|
|
|
|
|
|
|
|
|
Director |
|
|
Harry H. Penner, Jr. |
|
|
|
|
|
|
|
|
|
/s/ Karen Shoos Lipton |
|
Director |
|
June 17, 2008 |
Karen Shoos Lipton |
|
|
|
|
7
EXHIBIT INDEX
No. |
|
Description |
|
Location |
2.1 |
|
Agreement and Plan of Merger, dated as of October 19, 2007, by and among AVANT, Celldex Merger Corporation, and Celldex Therapeutics, Inc. |
|
Incorporated by reference to Exhibit 2.1 of AVANTs Registration Statement on Form S-4 (Reg. N. 333-148291), filed December 21, 2007 |
|
|
|
|
|
3.1 |
|
Third Restated Certificate of Incorporation of AVANT |
|
Incorporated by reference to Exhibit 3.1 of AVANTs Registration Statement on Form S-4 (Reg. No. 333-59215), filed July 16, 1998 |
|
|
|
|
|
3.2 |
|
Certificate of Amendment of Third Restated Certificate of Incorporation of AVANT |
|
Incorporated by reference to Exhibit 3.1 of AVANTs Registration Statement on Form S-4 (Reg. No. 333-59215), filed July 16, 1998 |
|
|
|
|
|
3.3 |
|
Second Certificate of Amendment of Third Restated Certificate of Incorporation of AVANT |
|
Incorporated by reference to Exhibit 3.2 of AVANTs Registration Statement on Form S-4 (Reg. No. 333-59215), filed July 16, 1998 |
|
|
|
|
|
3.4 |
|
Third Certificate of Amendment of Third Restated Certificate of Incorporation of AVANT |
|
Incorporated by reference to Exhibit 3.1 of AVANTs Quarterly Report on Form 10-Q, filed May 10, 2002 |
|
|
|
|
|
3.5 |
|
Amended and Restated By-Laws of AVANT as of March 14, 2007 |
|
Incorporated by reference to Exhibit 3.5 of AVANTs Annual Report on Form 10-K, filed March 18, 2008 |
|
|
|
|
|
3.6 |
|
Certificate of Elimination of Series C-1 Junior Participating Cumulative Preferred Stock |
|
Incorporated by reference to Exhibit 3.6 of AVANTs Annual Report on Form 10-K, filed March 16, 2005 |
|
|
|
|
|
3.7 |
|
Certificate of Designations, Preferences and Rights of a Series of Preferred Stock of AVANT Immunotherapeutics, Inc. classifying and designating the Series C-1 Junior Participating Cumulative Preferred Stock |
|
Incorporated by reference to Exhibit 3.1 of AVANTs Registration Statement on Form 8-A filed November 8, 2004 |
|
|
|
|
|
3.8 |
|
Fourth Certificate of Amendment of Third Restated Certificate of Incorporation of AVANT |
|
Incorporated by reference to Exhibit 3.1 of AVANTs Current Report on Form 8-K filed on March 11, 2008 |
|
|
|
|
|
3.9 |
|
Fifth Certificate of Amendment of Third Restated Certificate of Incorporation of AVANT |
|
Incorporated by reference to Exhibit 3.2 of AVANTs Current Report on Form 8-K filed on March 11, 2008 |
|
|
|
|
|
4.1 |
|
Shareholder Rights Agreement dated November 5, 2004 between AVANT and EquiServe Trust Company, N.A. as Rights Agent |
|
Incorporated by reference to Exhibit 4.1 of AVANTs Registration Statement on Form 8-A filed November 8, 2004 |
|
|
|
|
|
4.2 |
|
Amendment No. 1 to Shareholder Rights Agreement dated October 19, 2007 between AVANT and Computershare Trust Company, N.A. (formerly EquiServe Trust Company, N.A.) as Rights Agent |
|
Incorporated by reference to Exhibit 10.1 of AVANTs Registration Statement on Form 8-A/A filed October 22, 2007 |
|
|
|
|
|
4.3 |
|
Amendment No. 2 to Shareholder Rights Agreement dated November 5, 2004, between the Company and Computershare Trust Company, N.A. (formerly EquiServe Trust Company, N.A.), as Rights Agent. |
|
Incorporated by reference to Exhibit 10.1 of AVANTs Registration Statement on Form 8-A12G/A filed on March 7. 2008. |
|
|
|
|
|
5.1 |
|
Opinion of Goodwin Procter LLP as to the legality of the securities being registered |
|
Filed herewith |
|
|
|
|
|
10.1 |
|
Celldex Therapeutics, Inc. 2005 Equity Incentive Plan |
|
Filed herewith |
|
|
|
|
|
10.2 |
|
AVANT Immunotherapeutics, Inc. 2008 Stock Option and Incentive Plan |
|
Incorporated by reference to Exhibit 10.3 to a Current Report on Form 8-K filed by AVANT on October 22, 2007 |
|
|
|
|
|
23.1 |
|
Consent of PricewaterhouseCoopers LLP, Independent Registered Public Accounting Firm |
|
Filed herewith |
|
|
|
|
|
23.2 |
|
Consent of Ernst & Young LLP, Independent Registered Public Accounting Firm of Celldex Therapeutics, Inc. |
|
Filed herewith |
|
|
|
|
|
23.3 |
|
Consent of Goodwin Procter LLP |
|
Included in Exhibit 5.1 hereto |
|
|
|
|
|
24.1 |
|
Powers of Attorney |
|
Included on signature pages to this Registration Statement |
Indicates a management contract or compensation plan, contract or arrangement.
8
Exhibit 5.1
[Goodwin Procter LLP Letterhead]
June 17, 2008
AVANT Immunotherapeutics, Inc.
119 Fourth Avenue
Needham, MA 02494
|
Re: |
Securities Being Registered under Registration Statement on Form S-8 |
Ladies and Gentlemen:
This opinion letter is furnished to you in connection with your filing of a Registration Statement on Form S-8 (the Registration Statement) pursuant to the Securities Act of 1933, as amended (the Securities Act), on or about the date hereof relating to an aggregate of 2,946,914 shares (the Shares) of AVANT Immunotherapeutics, Inc. (the Company) Common Stock, $.001 par value per share (Common Stock), that may be issued in the following amounts: (i) 1,500,000 shares upon the exercise of options issued under the Companys 2008 Stock Option and Incentive Plan (the AVANT Plan), and (ii) 1,446,914 shares of Company Common Stock that may be issued upon the exercise of options issued under Celldex Therapeutics, Incs 2005 Equity Incentive Plan (the Celldex Plan), which options were assumed by the Company in connection with an Agreement and Plan of Merger, dated October 19, 2007, by and among the Company, Callisto Merger Corporation and Celldex Therapeutics, Inc.
We have reviewed such documents and made such examination of law as we have deemed appropriate to give the opinions expressed below. We have relied, without independent verification, on certificates of public officials and, as to matters of fact material to the opinion set forth below, on certificates of officers of the Company.
The opinion expressed below is limited to the Delaware General Corporation Law (which includes applicable provisions of the Delaware Constitution and reported judicial decisions interpreting the Delaware General Corporation Law and the Delaware Constitution ).
For purposes of the opinion expressed below, we have assumed that a sufficient number of authorized but unissued shares of the Companys Common Stock will be available for issuance when the Shares are issued.
Based on the foregoing, we are of the opinion that the Shares have been duly authorized and, upon issuance and delivery against payment therefor in accordance with the terms of the Plans, will be validly issued, fully paid and nonassessable.
We hereby consent to the inclusion of this opinion as Exhibit 5.1 to the Registration Statement. In giving our consent, we do not admit that we are in the category of persons whose consent is required under Section 7 of the Securities Act or the rules and regulations thereunder.
|
Very truly yours, |
|
|
|
/s/ Goodwin Procter LLP |
|
|
|
GOODWIN PROCTER LLP |
2
Exhibit 10.1
CELLDEX THERAPEUTICS, INC.
2005 EQUITY INCENTIVE PLAN
Section 1. Purpose of the Plan. The purpose of the Plan is to aid Celldex Therapeutics, Inc. and any Participating Company in securing and retaining Directors, Officers, Consultants, and other Employees and to motivate such persons to exert their best efforts on behalf of the Participating Company Group.
Section 2. Definitions and Construction. Whenever used herein, the following terms shall have their respective meanings set forth below:
(a) Affiliate means (i) an entity, other than a Parent Company, that directly, or indirectly through one or more intermediary entities, controls the Company or (ii) an entity, other than a Subsidiary Company, that is controlled by the Company directly, or indirectly through one or more intermediary entities. For this purpose, the term control (including the term controlled by) means the possession, direct or indirect, of the power to direct or cause the direction of the management and policies of the relevant entity, whether through the ownership of voting securities, by contract or otherwise; or shall have such other meaning assigned such term for the purposes of registration on Form S-8 under the Securities Act.
(b) Award means any Option, Stock Appreciation Right, Restricted Stock, Restricted Stock Unit, Performance Share, Performance Unit, Deferred Stock Award, Other Stock-based Award or Deferred Compensation Award granted under the Plan.
(c) Award Agreement means a written agreement between the Company and a Participant setting forth the terms, conditions and restrictions of the Award granted to the Participant. An Award Agreement may be an Option Agreement, a Stock Appreciation Right Agreement, a Restricted Stock Agreement, a Restricted Stock Unit Agreement, a Performance Share Agreement, a Performance Unit Agreement, a Deferred Stock Award Agreement, a Deferred Compensation Award Agreement and such other cash agreement or Stock-based Award Agreement containing such terms and conditions as shall be determined by the Committee from time to time.
(d) Board means the Board of Directors of the Company.
(e) Cashless Exercise shall have the meaning set forth in Section 6(d).
(f) Cause shall have the meaning set forth in Section 6(h).
(g) Change in Control means, unless otherwise defined by the Participants Award Agreement or contract of employment or service, the occurrence of any of the following:
(i) An acquisition (other than directly from the Company) of any voting securities of the Company (the Voting Securities) by any Person (as the term person is used for purposes of Section 13(d) or 14(d) of the Exchange Act) immediately after which such Person has Beneficial Ownership (within the
meaning of Rule 13d-3 promulgated under the Exchange Act) of 20% or more of the combined voting power of the Companys then outstanding Voting Securities; provided, however, that in determining whether a Change of Control has occurred, voting securities which are acquired in a Non-Control Acquisition (as hereinafter defined) shall not constitute an acquisition which would cause a Change of Control.
A Non-Control Acquisition shall mean an acquisition of Voting Securities by (1) an employee benefit plan (or a trust forming a part thereof) maintained by (x) the Company or (y) any company or other Person of which a majority of its voting power or its equity securities or equity interest is owned directly or indirectly by the Company (a Subsidiary), (2) any Parent Company, the Company or any Subsidiary, or (3) any Person in connection with a Non-Control Transaction (as defined below);
(ii) The individuals who, as of the Effective Date, are members of the Board (the Incumbent Board), cease for any reason to constitute at least 66 2/3% of the Board; provided, however, that if the election, or nomination for election by the Companys shareholders, of any new director was approved by a vote of at least 66 2/3% of the Incumbent Board, such new director shall be considered as a member of the Incumbent Board; provided, further, however, that no individual shall be considered a member of the Incumbent Board if such individual initially assumed office as a result of either an actual or threatened Election Contest (as described in Rule 14a-11 promulgated under the Exchange Act) or other actual or threatened solicitation of proxies or consents by or on behalf of a Person other than the Board (a Proxy Contest) including by reason of any agreement intended to avoid or settle any Election Contest or Proxy Contest; or
(iii) Approval of the Companys shareholders of: (1) a merger, consolidation or reorganization involving the Company, unless (i) the shareholders of the Company, immediately before such merger, consolidation or reorganization, own, directly or indirectly immediately following such merger, consolidation or reorganization, at least 66 2/3% of the combined voting power of the outstanding Voting Securities of the company resulting from such merger, consolidation or reorganization (the Surviving Company) in substantially the same proportion as their ownership of the Voting Securities immediately before such merger, consolidation or reorganization, (ii) the individuals who were members of the Incumbent Board immediately prior to the execution of the agreement providing for such merger, consolidation or reorganization constitute at least 66 2/3% of the members of the board of directors of the Surviving Company, and (iii) no Person, other than the Company, any Subsidiary, any employee benefit plan (or any trust forming a part thereof) maintained by the Company, the Surviving Company or any subsidiary thereof, or any Person who, immediately prior to such merger, consolidation or reorganization had Beneficial Ownership of 20% or more of the then outstanding Voting Securities of the Company, has Beneficial Ownership of 20% or more of the combined voting power of the
2
Surviving Companys then outstanding voting securities (a transaction described in clause (i) through (iii) shall herein be referred to as a Non-Control Transaction); (2) a complete liquidation or dissolution of the Company; or (3) an agreement for the sale or other disposition of all or substantially all of the assets of the Company to any Person (other than a transfer to a Subsidiary).
Notwithstanding the foregoing, a Change of Control shall not be deemed to occur solely because any Person (the Subject Person) acquired Beneficial Ownership of more than the permitted amount of the outstanding Voting Securities as a result of the acquisition of Voting Securities by the Company which, by reducing the number of Voting Securities outstanding, increases the proportional number of shares Beneficially Owned by the Subject Person, provided that if a Change of Control would occur (but for the operation of this sentence) as a result of the acquisition of Voting Securities by the Company, and after such share acquisition, the Subject Person becomes the Beneficial Owner of any additional Voting Securities which increases the percentage of the then outstanding Voting Securities Beneficially Owned by the Subject Person, then a Change of Control shall occur.
(h) Code means the Internal Revenue Code of 1986, as amended, and any applicable regulations promulgated thereunder.
(i) Committee means the Companys Compensation Committee and such other committee or subcommittee of the Board, if any, duly appointed to administer the Plan and having such powers in each instance as shall be specified by the Board. The Committee shall have at least two members, each of whom shall be a non-employee director as defined in Rule 16b-3 under the Exchange Act and an outside director as defined in Section 162(m) of the Code and the regulations thereunder, and, if applicable, meet the independence requirements of the United States Securities and Exchange Commission and any applicable stock exchange, quotation system or other self-regulatory organization on which the Stock is traded. If, at any time, there is no committee of the Board then authorized or properly constituted to administer the Plan, the Board shall exercise all of the powers of the Committee granted herein.
(j) Company means Celldex Therapeutics, Inc., a Delaware corporation, or any successor company thereto.
(k) Consultant means a person engaged to provide consulting or advisory services (other than as an Employee or a member of the Board) to a Participating Company, provided that the identity of such person, the nature of such services or the entity to which such services are provided would not preclude the Company from offering or selling securities to such person pursuant to the Plan in reliance on registration on a Form S-8 Registration Statement under the Securities Act.
(l) Covered Employee shall have the meaning given to such term in Section 162(m) of the Code.
(m) Deferral Period shall have the meaning set forth in Section 11(a).
(n) Deferred Compensation Award means an award granted to a Participant pursuant to Section 13 of the Plan.
3
(o) Deferred Stock Award means an award of Stock granted to a Participant pursuant to Section 11 of the Plan.
(p) Director means a member of the Board.
(q) Disability means a condition causing a Participant to be disabled within the meaning of Section 409A(a)(2)(C) of the Code.
(r) Dividend Equivalent means a credit, made at the discretion of the Committee or as otherwise provided by the Plan, to the account of a Participant in an amount equal to the cash dividends paid on one share of Stock for each share of Stock represented by an Award held by such Participant.
(s) Effective Date means May , 2005, the date that the Plan is approved by the holders of a majority of shares of the outstanding Stock of the Company.
(t) Elective Deferred Period shall have the meaning set forth in Section 11(b)(v).
(u) Employee means any person treated as an employee (including an Officer or a member of the Board who is also treated as an employee) in the records of a Participating Company and, with respect to any Incentive Stock Option granted to such person, who is an employee for purposes of Section 422 of the Code; provided, however, that neither service as a member of the Board nor payment of a directors fee shall be sufficient to constitute employment for purposes of the Plan. For purposes of the Plan, the Committee shall determine in good faith and in the exercise of its discretion whether an individual has become or has ceased to be an Employee and the effective date of such individuals employment or termination of employment, as the case may be. For purposes of an individuals rights, if any, under the Plan as of the time of the Committees determination, all such determinations by the Committee shall be final, binding and conclusive, notwithstanding that the Committee or any court of law or governmental agency subsequently makes a contrary determination.
(v) Exchange Act means the Securities Exchange Act of 1934, as amended.
(w) Fair Market Value means, as of any date, the value of a share of Stock or other property as determined by the Committee, in its discretion, or by the Company, in its discretion, if such determination is expressly allocated to the Company herein, subject to the following:
(i) Except as otherwise determined by the Committee, if, on such date, the Stock is listed on a national or regional securities exchange or market system, the Fair Market Value of a share of Stock shall be the closing price of a share of Stock (or the mean of the closing bid and asked prices of a share of Stock if the Stock is so quoted instead) as quoted on the Nasdaq National Market, the Nasdaq SmallCap Market or such other national or regional securities exchange or market system constituting the primary market for the Stock, as reported in The Wall Street Journal or such other source as the Company deems reliable. If the
4
relevant date does not fall on a day on which the Stock has traded on such securities exchange or market system, the date on which the Fair Market Value shall be established shall be the last day on which the Stock was so traded prior to the relevant date, or such other appropriate day as shall be determined by the Committee, in its discretion.
(ii) Notwithstanding the foregoing, the Committee may, in its discretion, determine the Fair Market Value on the basis of the opening, closing, high, low or average sale price of a share of Stock or the actual sale price of a share of Stock received by a Participant, on such date, the preceding trading day or the next succeeding trading day. The Committee may vary its method of determination of the Fair Market Value as provided in this Section for different purposes under the Plan.
(iii) If, on such date, the Stock is not listed on a national or regional securities exchange or market system, the Fair Market Value of a share of Stock shall be as determined by the Committee in good faith without regard to any restriction other than a restriction which, by its terms, will never lapse.
(x) Full Value Award means any of the following types of Awards to the extent such Awards are settled in shares of Stock: Restricted Stock; Restricted Stock Units; Performance Shares; Performance Units; Deferred Stock Awards; and Other Stock-based Awards.
(y) Incentive Stock Option means an Option intended to be (as set forth in the Award Agreement) and which qualifies as an incentive stock option within the meaning of Section 422(b) of the Code.
(z) Insider means an Officer, a Director or any other person whose transactions in Stock are subject to Section 16 of the Exchange Act.
(aa) Nonqualified Stock Option means an Option not intended to be (as set forth in the Award Agreement) or not qualifying as an incentive stock option within the meaning of Section 422(b) of the Code.
(bb) Officer means any person designated by the Board as an officer of the Company.
(cc) Option means the right to purchase Stock at a stated price for a specified period of time granted to a Participant pursuant to Section 6 of the Plan. An Option may be either an Incentive Stock Option or a Nonqualified Stock Option.
(dd) Option Expiration Date shall have the meaning set forth in Section 6(f).
(ee) Other Stock-based Awards means awards that are valued in whole or in part by reference to or are otherwise based on the Stock, including without limitation, convertible debentures, but excluding Options, Restricted Stock Awards, Restricted Stock Units,
5
Performance Awards, Stock Appreciation Rights, Deferred Stock Awards and Deferred Compensation Awards.
(ff) Parent Company means any present or future parent company of the Company, as defined in Section 424(e) of the Code.
(gg) Participant means any eligible person under the Plan who has been granted one or more Awards.
(hh) Participating Company means the Company or any Subsidiary Company or Affiliate.
(ii) Participating Company Group means, at any point in time, all entities collectively which are then Participating Companies.
(jj) Performance Award means an Award of Performance Shares or Performance Units.
(kk) Performance Award Formula means, for any Performance Award, a formula or table established by the Committee pursuant to Section 10 of the Plan which provides the basis for computing the value of a Performance Award at one or more threshold levels of attainment of the applicable Performance Goal(s) measured as of the end of the applicable Performance Period.
(ll) Performance Goal means a performance goal established by the Committee pursuant to Section 10 of the Plan.
(mm) Performance Measure shall have the meaning set forth in Section 10(d).
(nn) Performance Period means a period established by the Committee pursuant to Section 10(c) of the Plan at the end of which one or more Performance Goals are to be measured.
(oo) Performance Share means a bookkeeping entry representing a right granted to a Participant pursuant to Section 10 of the Plan to receive a payment equal to the Fair Market Value of a share of Stock, based upon a Performance Award Formula.
(pp) Performance Targets shall have the meaning set forth in Section 10(d).
(qq) Performance Unit means a bookkeeping entry representing a right granted to a Participant pursuant to Section 10 of the Plan to receive a payment of up to $100, as determined by the Committee, based upon a Performance Award Formula.
(rr) Plan means the Companys 2005 Equity Incentive Plan.
6
(ss) Predecessor Plan means each of the Companys 2003 Long-Term Incentive Stock Plan.
(tt) Restricted Stock Award means an Award of Restricted Stock.
(uu) Restricted Stock means Stock granted to a Participant pursuant to Section 8 of the Plan.
(vv) Restricted Stock Unit or Stock Unit means a bookkeeping entry representing a right granted to a Participant pursuant to Section 9 of the Plan, to receive a share of Stock on a date determined in accordance with the provisions of Section 9 and the Participants Award Agreement.
(ww) Restriction Period means the period established in accordance with Section 8 of the Plan during which shares subject to a Restricted Stock Award are subject to Vesting Conditions.
(xx) Rule 16b-3 means Rule 16b-3 under the Exchange Act, as amended from time to time, or any successor rule or regulation.
(yy) SAR or Stock Appreciation Right means a bookkeeping entry representing, for each share of Stock subject to such SAR, a right granted to a Participant pursuant to Section 7 of the Plan to receive payment of an amount equal to the excess, if any, of the Fair Market Value of a share of Stock on the date of exercise of the SAR over the exercise price.
(zz) Section 162(m) means Section 162(m) of the Code.
(aaa) Securities Act means the Securities Act of 1933, as amended.
(bbb) Service means a Participants employment or service with the Participating Company Group, whether in the capacity of an Employee, Officer, Director or Consultant. Unless otherwise provided by the Committee, a Participants Service shall not be deemed to have terminated merely because of a change in the capacity in which the Participant renders such Service or a change in the Participating Company for which the Participant renders such Service, provided that there is no interruption or termination of the Participants Service. Furthermore, a Participants Service shall not be deemed to have terminated if the Participant takes any military leave, sick leave, or other bona fide leave of absence that is approved by the Company and otherwise complies with the provisions of Section 14 of the Plan. A Participants Service shall be deemed to have terminated either upon an actual termination of employment or service with the Participating Company Group or upon the entity for which the Participant performs Service ceasing to be a Participating Company. Subject to the foregoing, the Company, in its discretion, shall determine whether the Participants Service has terminated and the effective date of such termination.
(ccc) Spread shall have the meaning set forth in Section 21(a)(3).
7
(ddd) Stock means the common stock of the Company, as adjusted from time to time in accordance with Section 4(c) of the Plan.
(eee) Stock Unit means a bookkeeping entry representing a right granted to a Participant pursuant to Section 13 of the Plan to receive a share of Stock on a date determined in accordance with the provisions of Section 13 and the Participants Award Agreement, if any.
(fff) Subsidiary Company means any present or future subsidiary company of the Company, as defined in Section 424(f) of the Code.
(ggg) Ten Percent Owner or 10% Owner means a Participant who, at the time an Option is granted to the Participant, owns stock possessing more than ten percent (10%) of the total combined voting power of all classes of stock of a Participating Company (other than an Affiliate) within the meaning of Section 422(b)(6) of the Code.
(hhh) Vesting Conditions mean those conditions established in accordance with Section 8 or Section 9 of the Plan prior to the satisfaction of which shares subject to a Restricted Stock Award or Restricted Stock Unit Award, respectively, remain subject to forfeiture or a repurchase option in favor of the Company upon the Participants termination of Service.
Captions and titles contained herein are for convenience only and shall not affect the meaning or interpretation of any provision of the Plan. Except when otherwise indicated by the context, the singular shall include the plural and the plural shall include the singular. Use of the term or is not intended to be exclusive, unless the context clearly requires otherwise.
Section 3. Administration.
(a) The Plan shall be administered by the Committee. All questions of interpretation of the Plan or of any Award shall be determined by the Committee, and such determinations shall be final and binding upon all persons having an interest in the Plan or such Award. A majority of the whole Committee present at a meeting at which a quorum is present, or an act approved in writing by all members of the Committee, shall be an act of the Committee. The Committee shall have full power and authority, subject to such resolutions not inconsistent with the provisions of the Plan as may from time to time be issued or adopted by the Board, to grant Awards to Participants, pursuant to the provisions of the Plan. The Committee shall also interpret the provisions of the Plan and any Award issued under the Plan (and any agreements relating thereto) and supervise the administration of the Plan.
(b) The Committee shall: (i) select the Participants to whom Awards may from time to time be granted hereunder; (ii) determine whether Incentive Stock Options, Nonqualified Stock Options, Stock Appreciation Rights, Restricted Stock, Deferred Stock Awards, Restricted Stock Units, Performance Shares, Performance Units, Other Stock-based Awards, or Deferred Compensation Awards, or a combination of the foregoing, are to be granted hereunder; (iii) determine the number of shares of Stock to be covered by each Award granted hereunder; (iv) determine the terms, conditions and restrictions applicable to each Award (which need not be identical) and any shares acquired pursuant thereto, including, without limitation, (A) the exercise or purchase price of Stock purchased pursuant to any Award, (B) the method of
8
payment for Stock purchased pursuant to any Award, (C) the method for satisfaction of any tax withholding obligation arising in connection with any Award, including by the withholding or delivery of shares of Stock, (D) the timing, terms and conditions of the exercisability or vesting of any Award or any shares acquired pursuant thereto, (E) the Performance Award Formula and Performance Goals applicable to any Award and the extent to which such Performance Goals have been attained, (F) the time of the expiration of any Award, (G) the effect of the Participants termination of Service on any of the foregoing, and (H) all other terms, conditions and restrictions applicable to any Award or Stock acquired pursuant thereto not inconsistent with the terms of the Plan; (v) determine whether, to what extent and under what circumstances Awards may be settled in cash; (vi) determine whether, to what extent, and under what circumstances Stock and other amounts payable with respect to an Award under this Plan shall be deferred either automatically or at the election of the Participant; and (vii) determine whether, to what extent, and under what circumstances Option grants and/or other Awards under the Plan are to be made, and operate, on a tandem basis.
(c) The Chief Executive Officer and the Chief Financial Officer or any other Officer designated by the Committee shall have the authority to act on behalf of the Company with respect to any matter, right, obligation, determination or election which is the responsibility of or which is allocated to the Company herein. The Board or the Committee may, in its discretion, delegate to a committee comprised of one or more Officers the authority to grant one or more Awards, without further approval of the Board or the Committee, to any Employee, other than a person who, at the time of such grant, is an Insider; provided, however, that (i) such Awards shall not be granted for shares of Stock in excess of the maximum aggregate number of shares of Stock authorized for issuance pursuant to Section 4, (ii) the exercise price per share of each such Award which is an Option or Stock Appreciation Right shall be not less than the Fair Market Value per share of the Stock on the effective date of grant (or, if the Stock has not traded on such date, on the last day preceding the effective date of grant on which the Stock was traded), and (iii) each such Award shall be subject to the terms and conditions of the appropriate standard form of Award Agreement approved by the Board or the Committee and shall conform to the provisions of the Plan and such other guidelines as shall be established from time to time by the Board or the Committee.
(d) With respect to participation by Insiders in the Plan, at any time that any class of equity security of the Company is registered pursuant to Section 12 of the Exchange Act, the Plan shall be administered in compliance with the requirements, if any, of Rule 16b-3.
(e) No member of the Committee shall be liable for any action or determination made in good faith with respect to the Plan or any Award thereunder.
Notwithstanding the foregoing, without the affirmative vote of holders of a majority of the shares of Stock cast in person or by proxy at a meeting of the shareholders of the Company at which a quorum representing a majority of all outstanding shares of Stock is present or represented by proxy, the Board shall not approve a program providing for either (i) the cancellation of outstanding Options or SARs and the grant in substitution therefore of new Options or SARs having a lower exercise price or (ii) the amendment of outstanding Options or SARs to reduce the exercise price thereof. This paragraph shall not be construed to apply to issuing or assuming
9
a stock option in a transaction to which section 424(a) applies, within the meaning of Section 424 of the Code.
Section 4. Stock Subject to the Plan; Individual Limitations on Awards.
(a) Subject to adjustment as provided in subsections (b) and (c) below, the maximum aggregate number of shares of Stock that may be issued under the Plan shall be 1,500,000 shares and shall consist of (i) authorized but unissued shares, (ii) or reacquired shares (treasury) of Stock, or (iii) any combination thereof. Notwithstanding the foregoing, no more than ten percent (10%) of the maximum aggregate number of shares of Stock that may be issued under the Plan, shall be issued pursuant to the exercise or settlement of Full Value Awards.
If an outstanding Award for any reason expires or is terminated or canceled without having been exercised or settled in full, or if shares of Stock acquired pursuant to an Award subject to forfeiture or repurchase are forfeited or repurchased by the Company at the Participants purchase price, the shares of Stock allocable to the terminated portion of such Award or such forfeited or repurchased shares of Stock shall again be available for issuance under the Plan. Shares of Stock shall not be deemed to have been issued pursuant to the Plan (i) with respect to any portion of an Award that is settled in cash or (ii) to the extent such shares are withheld or reacquired by the Company in satisfaction of tax withholding obligations pursuant to Section 19. Upon payment in shares of Stock pursuant to the exercise of a SAR, the number of shares available for issuance under the Plan shall be reduced only by the number of shares actually issued in such payment. If the exercise price of an Option is paid by tender to the Company, or attestation to the ownership, of shares of Stock owned by the Participant, the number of shares available for issuance under the Plan shall be reduced by the net number of shares for which the Option is exercised. The maximum number of shares available for issuance under the Plan shall not be reduced to reflect any dividends or dividend equivalents that are reinvested into additional shares of Stock or credited as additional Performance Shares. The maximum number of shares of Stock shall not be reduced by the issuance of shares of Stock hereunder due to the assumption, conversion or substitution of Awards made by an entity acquired by the Company. For the purposes of computing the total number of shares of Stock granted under the Plan, where one or more types of Awards, both of which are payable in shares of Stock, are granted in tandem with each other, such that the exercise of one type of Award with respect to a number of shares cancels an equal number of shares of the other, the number of shares granted under both Awards shall be deemed to be equivalent to the number of shares under one of the Awards.
(b) The maximum aggregate number of shares of Stock that may be issued under the Plan as set forth in subsection (a) above shall be cumulatively increased from time to time by:
(i) the number of shares of Stock authorized and remaining available for the future grant of options under the Predecessor Plan as of the Effective Date;
(ii) the number of shares of Stock subject to that portion of any option outstanding under a Predecessor Plan as of the Effective Date which, on or after the Effective Date, expires or is terminated or canceled for any reason without having been exercised; and
10
Notwithstanding the foregoing, the aggregate number of shares of Stock authorized for issuance under the Predecessor Plan that may become authorized for issuance under the Plan pursuant to this subsection (b) shall not exceed 2,000,000 shares. As a result, the maximum aggregate number of shares of Stock that may be issued under the Plan, inclusive of the shares previously issuable under the Predecessor Plan, is 3,500,000 shares.
The Plan shall serve as the successor to the Predecessor Plan, and no further option grants shall be made under the Predecessor Plan. All options outstanding under the Predecessor Plan as of the Effective Date shall, immediately upon the Effective Date, be incorporated into the Plan and treated as outstanding Options under the Plan. However, each outstanding option so incorporated shall continue to be governed solely by the terms of the documents evidencing such option. No provision of the Plan shall be deemed to adversely affect or otherwise diminish the rights or obligations of the holders of such incorporated options with respect to their acquisition of shares of Stock which may exist under the terms of the Predecessor Plan under which such incorporated option was issued. Subject to the rights of the Participant under the incorporated option documents and Predecessor Plan, the discretion delegated to the Committee hereunder may be exercisable with respect to incorporated options to the same extent as it is exercisable with respect to options originally granted under this Plan.
Notwithstanding the foregoing, an Option may not be exercised by tender to the Company, or attestation to the ownership, of shares of Stock to the extent such tender or attestation would constitute a violation of the provisions of any law, regulation or agreement restricting the redemption of the Companys stock. Unless otherwise provided by the Committee, an Option may not be exercised by tender to the Company, or attestation to the ownership, of
14
shares of Stock unless such shares either have been owned by the Participant for more than six (6) months (and not used for another Option exercise by attestation during such period) or were not acquired, directly or indirectly, from the Company.
The Company reserves, at any and all times, the right, in the Companys sole and absolute discretion, to establish, decline to approve or terminate any program or procedures for the exercise of Options by means of a Cashless Exercise, including with respect to one or more Participants specified by the Company, notwithstanding that such program or procedures may be available to other Participants.
The transferability of this certificate and the shares of stock represented hereby are subject to the terms and conditions (including forfeiture) of the Celldex Therapeutics, Inc. 2005 Equity Incentive Plan and an Agreement entered into between the registered owner and Celldex Therapeutics, Inc. Copies of such Plan and Agreement are on file in the offices of Celldex Therapeutics, Inc
The Committee shall require that the stock certificates evidencing such shares be held in custody by the Company until the restrictions thereon shall have lapsed, and shall require, as a condition of any Restricted Stock Award, that the Participant shall have delivered a stock power, endorsed in blank, relating to the Stock covered by such Award.
The Committee may amend the terms of any Award theretofore granted, prospectively or retroactively, but no such amendment shall impair the rights of any holder without such holders consent. Notwithstanding the foregoing, the Board or the Committee may, in its discretion, amend the Plan or terms of any outstanding Award held by a person then subject to Section 16 of the Exchange Act without the consent of any holder in order to preserve exemptions under said Section 16 which are or become available from time to time under rules of the Securities and Exchange Commission.
(f) Excise Tax Limit. In the event that the vesting of Awards together with all other payments and the value of any benefit received or to be received by a Participant would result in all or a portion of such payment being subject to the excise tax under Section 4999 of the Code, then the Participants payment shall be either (i) the full payment or (ii) such lesser amount that would result in no portion of the payment being subject to excise tax under Section 4999 of the Code (the Excise Tax), whichever of the foregoing amounts, taking into account the applicable federal, state, and local employment taxes, income taxes, and the Excise Tax, results in the receipt by the Participant, on an after-tax basis, of the greatest amount of the
33
payment notwithstanding that all or some portion of the payment may be taxable under Section 4999 of the Code. All determinations required to be made under this Section 21(f) shall be made by the nationally recognized accounting firm which is the Companys outside auditor immediately prior to the event triggering the payments that are subject to the Excise Tax (the Accounting Firm). The Company shall cause the Accounting Firm to provide detailed supporting calculations of its determinations to the Company and the Participant. All fees and expenses of the Accounting Firm shall be borne solely by the Company. The Accounting Firms determinations must be made with substantial authority (within the meaning of Section 6662 of the Code). For the purposes of all calculations under Section 280G of the Code and the application of this Section 21(f), all determinations as to present value shall be made using 120 percent of the applicable Federal rate (determined under Section 1274(d) of the Code) compounded semiannually, as in effect on December 30, 2004.
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We hereby consent to the incorporation by reference in this Registration Statement on Form S-8 of our report dated March 18, 2008 relating to the financial statements and the effectiveness of internal control over financial reporting, which appears in AVANT Immunotherapeutics, Inc.s Annual Report on Form 10-K for the year ended December 31, 2007.
/s/ PricewaterhouseCoopers LLP
Boston, Massachusetts
June 17, 2008
Exhibit 23.2
Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in this Registration Statement on Form S-8 of AVANT Immunotherapeutics, Inc. pertaining to the Celldex Therapeutics, Inc. 2005 Equity Incentive Plan of our report dated May 7, 2008, with respect to the consolidated financial statements of Celldex Therapeutics, Inc. and Subsidiary included in the Current Report on Form 8-K/A of AVANT Immunotherapeutics, Inc., filed with the Securities and Exchange Commission on May 23, 2008.
/s/ Ernst & Young LLP
Metro Park, New Jersey
June 17, 2008
1